EURONEXT NV

First‑half 2026 update: Euronext NV reports strong sales of its spinal‑cord stimulator, a growing BCI platform, and a fortified balance sheet, positioning it for future approvals and market expansion.

Explore Euronext NV’s 2026 factsheet: closed‑ended fund, dual listing, and regulatory focus. Understand its governance, ESG gaps, and growth chances in Europe.

DNPP’s €10 per share takeover of AUSTRIACARD adds a major European payment and financing platform, offering cross‑border synergies while awaiting FDI approval and potential delisting.

EURONEXT NV’s 31‑July 2026 trading snapshot shows stable prices, modest growth, and a new dividend policy, while uncovering digital‑asset and AI opportunities amid regulatory shifts.

EURONEXT NV strengthens shareholder value with a major share‑buyback and board refresh, boosting governance, investor clarity, and long‑term confidence across markets.

Discover how Xryma Plc’s pre‑listing liquidity plan and book‑building pricing aim to secure an Euronext Paris licence while boosting investor confidence and market stability.

EURONEXT NV extends its 2022 credit lines to 2030, converts exit fees into a 2031 P‑IK, and plans a Growth Paris listing plus convertible bonds—boosting liquidity, reducing debt costs, and driving shareholder value.

EURONEXT NV’s latest capital raise and buy‑back strategy balances share dilution with employee ownership, aiming to strengthen its balance sheet and fuel future growth in a regulated European market.

SoftOx Solutions’ SIS‑03 phase 2a shows safe, effective inhaled therapy for chronic airway infections, boosting investor confidence and market potential.

Explore how Ramsay Santé’s debt refinancing and KNDS NV’s dual‑exchange IPO reshape investment strategies across Euronext Paris, highlighting capital‑optimisation, ESG compliance, and defence‑sector growth.